The US vaccine industry is facing a chilling effect as Health Secretary Robert F. Kennedy Jr.'s anti-vaccine rhetoric translates into policy changes. These changes have led to a reduction in vaccine usage, impacting the investment case for biotechs and causing revenue and cost concerns for vaccine manufacturers. Kennedy's appointment has raised concerns among investors and analysts, who initially saw it as a headline risk rather than a fundamental threat. However, as the risks become more tangible, investors are worried that Kennedy's policies will be difficult to reverse, potentially leading to preventable illnesses and deaths. Kennedy argues that the changes aim to improve safety and align US vaccine policy with other nations. Despite the challenges, vaccine makers remain confident in the long-term prospects of their industry, as vaccines are still the most effective tool for disease prevention. However, they acknowledge that companies are now more susceptible to the political whims of leaders, making investment less predictable. The impact of US policy changes is already evident, with lower flu vaccine sales reported by GSK and Sanofi in the third quarter. The situation has sparked public rebukes from industry leaders, with Pfizer and Sanofi CEOs criticizing Kennedy's rhetoric. As the debate continues, investors remain cautious, and the future of the vaccine industry hangs in the balance.
